Overview

Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Status:
Not yet recruiting
Trial end date:
2027-10-06
Target enrollment:
Participant gender:
Summary
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca